SCYNEXIS to Present Data on Oral Ibrexafungerp at IDWeek 2021 from Interim Analyses of Phase 3 FURI Clinical Trial Showing Therapeutic Response Rates in Patients with Mucocutaneous and Invasive Fungal InfectionsGlobeNewsWire • 09/23/21
SCYNEXIS Announces U.S. Availability of BREXAFEMME® (ibrexafungerp tablets), the First New Antifungal Class of Therapy Approved by the U.S. FDA for Vaginal Yeast Infections in More Than 20 YearsGlobeNewsWire • 09/22/21
SCYNEXIS Announces Hansoh Pharma's Application to National Medical Products Administration (NMPA) in China for Phase 3 Trial of Ibrexafungerp for Treatment of Vulvovaginal Candidiasis (VVC)GlobeNewsWire • 09/13/21
SCYNEXIS Reports Second Quarter 2021 Financial Results and Provides Corporate UpdateGlobeNewsWire • 08/16/21
SCYNEXIS to Present Commercial Launch Update for BREXAFEMME® (ibrexafungerp tablets)GlobeNewsWire • 06/23/21
SCYNEXIS Confirms that BREXAFEMME® (ibrexafungerp tablets) Qualifies for 10 Years of Regulatory Exclusivity for Vaginal Yeast InfectionsGlobeNewsWire • 06/09/21
Scynexis Scores FDA Nod For Brexafemme, Oral Treatment For Vaginal Yeast InfectionBenzinga • 06/02/21
SCYNEXIS Announces FDA Approval of BREXAFEMME® (ibrexafungerp tablets) as the First and Only Oral Non-Azole Treatment for Vaginal Yeast InfectionsGlobeNewsWire • 06/02/21
SCYNEXIS Reports First Quarter 2021 Financial Results and Provides Corporate UpdateGlobeNewsWire • 05/17/21
Scynexis Raises $60M Via Term Loan Ahead Of Expected Approval Of Vaginal Yeast Infection TreatmentBenzinga • 05/14/21
SCYNEXIS Secures Term Loan Facility for up to $60 Million with Hercules Capital and Silicon Valley BankGlobeNewsWire • 05/14/21
SCYNEXIS Appoints Accomplished Commercial Executive Christine Coyne as Chief Commercial Officer to Lead the Brexafemme® LaunchGlobeNewsWire • 05/11/21
SCYNEXIS Presents Data at 2021 ACOG Demonstrating the Positive Outcome and Sustained Response of Investigational Oral Ibrexafungerp (Brexafemme™) in Difficult-to-Treat Patients with Vaginal Yeast InfectionsGlobeNewsWire • 04/30/21
SCYNEXIS Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate UpdateGlobeNewsWire • 03/29/21
SCYNEXIS Announces Positive Results from Interim Analyses of Ongoing Phase 3 Studies (FURI and CARES), Demonstrating Oral Ibrexafungerp's Ability to Treat Severe Fungal Infections in the Hospital SettingGlobeNewsWire • 03/02/21
SCYNEXIS to Participate in Maxim Group's Late Stage Innovations in Women's Health Virtual EventGlobeNewsWire • 02/25/21
SCYNEXIS and Amplity Health Announce Agreement to Support the Anticipated U.S. Commercialization of BrexafemmeTM (Ibrexafungerp) for Vaginal Yeast InfectionsGlobeNewsWire • 02/23/21
SCYNEXIS and Hansoh Pharma Announce Licensing Agreement and Strategic Partnership for Ibrexafungerp in Greater ChinaBusiness Wire • 02/17/21
SCYNEXIS Announces Licensing Agreement and Strategic Partnership with Hansoh Pharma for Rights to Ibrexafungerp in Greater ChinaGlobeNewsWire • 02/17/21
SCYNEXIS Announces Closing of $85 Million Public Offering of Common Stock, Pre-Funded Warrants and WarrantsGlobeNewsWire • 12/22/20
SCYNEXIS Announces Pricing of $85 Million Public Offering of Common Stock, Pre-Funded Warrants and WarrantsGlobeNewsWire • 12/17/20
SCYNEXIS Announces Launch of $50 Million Public Offering of Common Stock and WarrantsGlobeNewsWire • 12/16/20
SCYNEXIS Announces Advancement of Ibrexafungerp's Intravenous Formulation to Clinical Stage and Provides Further Updates on its Clinical Studies in Patients with Life-Threatening Fungal InfectionsGlobeNewsWire • 12/10/20